Vered Stearns, M.D.
Locations and Appointments
Please contact the doctor's office to verify that your insurance is accepted.
*Indicates this doctor is no longer accepting new patients with this insurance plan.
- HMO
- Medicare
- PPO
- EPO/POS
- CHP
- Blue Access
- Blue Connection
- EPO
- HMO
- Mediblue (Senior)
- PPO
- CBP
- Medicaid
- Medicare
- Freedom
- Liberty
- Medicare Advantage
- Metro/Core/Charter
- Community Plan
- Medicare
- HMO
- Medicare
About Vered Stearns, M.D.
I became interested in oncology before I even knew the meaning of the word. My grandfather died of cancer when I was just 5 years-old, and that was a turning point for me in which I decided that when I grew up, I wanted to become a doctor and cure cancer. While my understanding of oncology has since become more sophisticated, it’s important to me that I never lose my childhood enthusiasm for improving the welfare and wellbeing of those impacted by cancer. During my Hematology and Medical Oncology Fellowship, I first began to focus on breast cancer, and enjoyed the privilege of working with internationally recognized physician-scientists who were able to make an impact in both the laboratory and the clinic. This inspired me to want to continue to work to translate state-of-the-art research into the context of patient treatments and care. My long-term research goal is to improve current therapies by individualizing strategies for the treatment and prevention of breast cancer. My main investigations focus on biomarkers that may predict response to standard regimens used to treat and prevent breast cancer and to introduce new approaches. I have also conducted translational studies designed to improve wellness of those living with and beyond breast cancer.
Dr. Vered Stearns completed the equivalent of a B.S. degree at the Tel Aviv University, Sackler Faculty of Medicine in 1989. After relocating to the United States, Dr. Stearns transferred to and graduated from the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School with a medical degree (M.D.) in 1992. She completed a residency in Internal Medicine and a fellowship in Medical Oncology at the Georgetown University where she developed an interest in translational breast cancer research and spent two additional years as a research fellow.
Dr. Stearns was a faculty member at the Lombardi Comprehensive Cancer Center and the Georgetown University, and at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan before joining the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in 2002. She remained at Johns Hopkins and served in a variety of roles, including co-Director of the Breast Cancer Program, co-Director of the Breast and Ovarian Cancer Program, Director, Women’s Malignancies Disease Group and inaugural Medical Director of the Under Armour Breast Health Innovation Center, until being recruited to 91Â鶹¾«Æ· and New York-Presbyterian Hospital in 2023. At 91Â鶹¾«Æ·, Dr. Stearns is Director of Translational Breast Cancer Research at the Department of Medicine, and Associate Director for Clinical Services at the Meyer Cancer Center. Her role in the Meyer Cancer Center will allow her to develop programs and to mentor team members across diseases throughout Manhattan, Brooklyn and Queens.
Dr. Stearns’s long-term research goal is to improve current therapies by individualizing strategies for the treatment and prevention of breast cancer. The main focus of Dr. Stearns’s research includes the utilization of biomarkers to predict response to standard regimens used to treat and prevent breast cancer, and to introduce new interventions.
Dr. Stearns and colleagues from the Consortium On Breast Cancer Pharamcogenomics (COBRA) Group were the first to evaluate the role of genetic variants in candidate genes such as CYP2D6 in tamoxifen metabolism, safety, and efficacy. This work has been extended to evaluate